Chromocell Therapeutics (CHRO) Competitors $1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CHRO vs. NRSN, GRCE, MRNS, MAAQ, ALLK, INKT, FBLG, DYAI, RANI, and SCYXShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include NeuroSense Therapeutics (NRSN), Grace Therapeutics (GRCE), Marinus Pharmaceuticals (MRNS), Mana Capital Acquisition (MAAQ), Allakos (ALLK), MiNK Therapeutics (INKT), FibroBiologics (FBLG), Dyadic International (DYAI), Rani Therapeutics (RANI), and SCYNEXIS (SCYX). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Its Competitors NeuroSense Therapeutics Grace Therapeutics Marinus Pharmaceuticals Mana Capital Acquisition Allakos MiNK Therapeutics FibroBiologics Dyadic International Rani Therapeutics SCYNEXIS Chromocell Therapeutics (NYSE:CHRO) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk. Is CHRO or NRSN more profitable? Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% NeuroSense Therapeutics N/A N/A -445.40% Do institutionals and insiders believe in CHRO or NRSN? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by company insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate CHRO or NRSN? NeuroSense Therapeutics has a consensus target price of $14.00, indicating a potential upside of 632.98%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeuroSense Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, CHRO or NRSN? NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Chromocell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08NeuroSense TherapeuticsN/AN/A-$10.21M-$0.54-3.54 Does the media refer more to CHRO or NRSN? In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 1 mentions for NeuroSense Therapeutics and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score. Company Overall Sentiment Chromocell Therapeutics Neutral NeuroSense Therapeutics Neutral Which has more volatility & risk, CHRO or NRSN? Chromocell Therapeutics has a beta of 3.63, suggesting that its share price is 263% more volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. SummaryNeuroSense Therapeutics beats Chromocell Therapeutics on 8 of the 12 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$8.69M$205.22M$5.55B$20.71BDividend YieldN/AN/A5.22%3.71%P/E Ratio-1.08N/A27.6628.10Price / SalesN/A223.65419.2138.38Price / CashN/A22.4436.8922.53Price / Book-0.815.618.034.58Net Income-$7.38M-$96.61M$3.18B$985.54M7 Day Performance-90.07%-0.57%2.93%2.79%1 Month Performance-88.04%-3.74%1.72%4.37%1 Year Performance-89.11%10.50%34.39%15.08% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.34+6.3%N/A-89.1%$8.69MN/A-1.084Gap UpHigh Trading VolumeNRSNNeuroSense Therapeutics1.7112 of 5 stars$2.29+7.5%$14.00+511.4%+55.3%$31.30MN/A-4.2410GRCEGrace Therapeutics1.7684 of 5 stars$3.01+2.7%$12.00+298.7%N/A$30.52MN/A-2.59N/AMRNSMarinus Pharmaceuticals2.3379 of 5 stars$0.55-0.2%$3.92+613.3%-54.2%$30.32M$30.99M-0.22110News CoverageMAAQMana Capital AcquisitionN/A$3.70-0.3%N/A+603.6%$30.06MN/A0.001ALLKAllakos2.8748 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190INKTMiNK Therapeutics3.2702 of 5 stars$7.42-0.8%$37.50+405.4%-25.3%$29.61MN/A-2.9430FBLGFibroBiologics2.2982 of 5 stars$0.76+5.1%$13.00+1,616.4%-87.0%$28.98MN/A-3.6110Gap UpDYAIDyadic International2.004 of 5 stars$0.96+2.6%$6.00+523.7%-35.3%$28.95M$3.49M-4.817News CoverageGap DownRANIRani Therapeutics1.5116 of 5 stars$0.50+2.3%$7.33+1,362.3%-85.6%$28.83M$1.03M-0.51110SCYXSCYNEXIS0.2607 of 5 stars$0.73+0.0%N/A-60.9%$28.49M$3.75M-1.3060 Related Companies and Tools Related Companies NeuroSense Therapeutics Competitors Grace Therapeutics Competitors Marinus Pharmaceuticals Competitors Mana Capital Acquisition Competitors Allakos Competitors MiNK Therapeutics Competitors FibroBiologics Competitors Dyadic International Competitors Rani Therapeutics Competitors SCYNEXIS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CHRO Stock Alerts